The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical symptoms of these disorders. These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been suggested that the persisting therapeutic effects of psychedelics are attributable to a similar biological mechanism (39, 40).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [39]
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“5 mg per kg), and this effect was sustained for at least 72 hour”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Dissociative anaesthetics mimic the positive and the negative symptoms (social withdrawal and apathy) of schizophrenia through antagonism at NMDA ( N -methyl- D -aspartate) glutamate receptor”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Systemic administration of non-competitive NMDA antagonists, such as ketamine, PCP and MK-801 (also known as dizocilpine), in rats markedly increases glutamate release in the mPF”
BackgroundDavis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“and was rated as among the most personally meaningful experience”
Background(1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
(2009) · Elsevier eBooks · doi:10.1016/c2009-1-03742-3 · Cited by 1,308
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“These effects are probably due to a blockade of NMDA receptors on GABA (γ-aminobutyric acid)-ergic interneuron”
Background
Research works printed but not linked: 6
- Hofmann, A. in Chemical Constitution and Pharmacodynamic Actions (ed. Burger, A.) 169–235 (M.Dekker, New York, 1968).
- Dittrich, A. in 50 Years of LSD. Current Status and Perspectives of Hallucinogens (eds Pletscher, A. & Ladewig, D.) 101–118 (Parthenon, New York, 1994).
- Hoffer, A. in The Uses and Implications of Hallucinogenic Drugs (eds Aaronson, B. & Osmond, H.) 357–366 (Hogarth Press, London, 1970).
- Leuner, H. in 50 Years of LSD: Current Status and Perspectives of Hallucinogen Research (eds Pletscher, A. & Ladewig, D.) 175–189 (Parthenon, New York, 1994).
- Crocket, R., Sandison, R. A. & Walk, A. in Proc. R. Med–Psychol. Assoc. (Lewis & Co., London, 1963).
- Leuner H. in Ethnopsychotherapie (eds Dittrich, A. & Scharfetter, C.) 151–161 (Enke, Stuttgard, 1987)
Cited by
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
“As a 5-HT2A agonist, the psilocybin metabolite psilocin directly and indirectly affects various brain cortical and subcortical areas and alters brain network dynamics (Carhart-Harris et al., 2012, 2014; Vollenweider and Kometer, 2010).”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
“Vollenweider and Kometer (2010) suggested that indirect activation of glutamate networks by classic psychedelics may enhance neuroplasticity through stimulation of a-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid–type glutamate receptors and subsequent increase in the level of BDNF. SerumBDNF…”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
“Together, these data suggest that 5HT2A downregulation may explain some of the rapid and sustained anxiolytic effects of psilocybin (Vollenweider and Kometer, 2010).”
BackgroundEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
“This indirect evidence has led to the reasonable hypothesis that psychedelics promote structural and functional neural plasticity, although this assumption had never been rigorously tested (Bogenschutz and Pommy, 2012; Vollenweider and Kometer, 2010).”
BackgroundPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
“Although classic hallucinogens bind to many serotonin receptor subtypes and other receptors (Ray, 2010), the psychoactive effects of all classic hallucinogens appear to depend primarily on their actions at 5HT2A receptors (Nichols, 2004; Vollenweider and Kometer 2010; Vollenweider et al., 1998).”
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914
“Several plausible mechanisms of hallucinogen-facilitated treatments have been proposed (Bogenschutz and Pommy, 2012; Carhart-Harris et al., 2012, 2014; Ross, 2012; Vollenweider and Kometer, 2010).”
BackgroundMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
“Recent reviews have suggested that hallucino-gens could have positive effects on the outcomes of clinical disorders, particularly anxiety and mood disorders (Griffiths and Grob, 2010; Vollenweider and Kometer, 2010).”
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
“Additionally, research with serotonergic psychedelics has gained momentum (Vollenweider and Kometer, 2010).”
BackgroundInfluentialPsychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
“Like ketamine, the classic psychedelics are also potent modulators of glutaminergic activity in prefrontal circuits (133).”
BackgroundInfluentialPsychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570
Self-citationSteiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568
“Here we present the first study providing evidence that supports a disease-related upregulation of microglial QUIN in depressive disorders, particularly in brain regions known to be responsive to infusion of NMDA antagonists such as ketamine [55].”
BackgroundInfluentialJohnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
“At the biological level, such explanations have focused on the molecular and neurological actions of these drugs involving serotonergic, glutamatergic, and dopaminergic signaling, as well as local brain metabolic activity and functional connectivity among brain regions including the amygdala, thalamus, and anterior an…”
BackgroundPrognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI).
Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00269 · Cited by 470
“…psilocybin (Griffiths et al., 2008, 2011), lysergic acid diethylamide (LSD; Goodman, 2002; Lyvers and Meester, 2012), and dimethyltryptamine (DMT; Trichter et al., 2009), as well as with other psychoactive substances such as nitrous oxide (James, 1882) and ketamine (Vollenweider and Kometer, 2010).”
BackgroundGasser, P., Kirchner, K., & Passie, T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114555249 · Cited by 456
“Repeat administration leads to rapid desensitization, but it appears to be possible that the effects of increased BDNF on neuronal and synaptic formation and functioning contribute to the sustained psychological effects of some hallucinogens (Vollenweider and Kometer 2010).”
BackgroundInfluentialAcute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 411
“In particular, LSD produced 30% higher ratings for oceanic boundlessness (mostly blissful state), 30% higher ratings for anxious ego dissolution, and 63% higher ratings for visionary restructuralization (mostly greater audiovisual synesthesia) compared with a high dose of psilocybin (55,57).”
BackgroundSelf-citationMultiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 411
“Although neglected for several decades, clinical testing of hallucinogens has resumed in recent years (Vollenweider and Kometer, 2010).”
BackgroundHendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 381
“Western science devoted significant attention to classic psychedelics from the 1950s through the early 1970s, and though a lack of modern methodological rigor complicates interpretation, results suggested that classic psychedelics might potentiate psychotherapeutic effectiveness (Johnson et al., 2008; Nichols, 2004; V…”
BackgroundInfluentialPrediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369
“Since human hallucinogen research has been dormant for almost three decades and has only come to a revival recently [8], most of what we know today about non-pharmacological predictors of hallucinogen response is based on a small number of older studies, many of which do not conform to modern methodological standards.”
BackgroundInfluentialSelf-citationKometer, M., Schmidt, A., Jancke, L., & Vollenweider, F. X. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3007-12.2013 · Cited by 355
“Furthermore, activation of 5-HT2A receptors predominantly mediates the visual hallucinations that are induced by serotonergic hallucinogens, such as psilocybin and LSD (Nichols, 2004; Vollenweider and Kometer, 2010), whereas the 5-HT2A receptor inverse agonist pimavanserin is effective for treatment of visual hallucin…”
BackgroundSelf-citationKraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323
Self-citationBlinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
LSD‐induced entropic brain activity predicts subsequent personality change
Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23234 · Cited by 303
“, 2003]—which would be at loggerheads with the drug-assisted psychotherapeutic model touted here and elsewhere [Bogenschutz et al., 2015; Gasser et al., 2015; Grob et al., 2011; Osorio Fde et al., 2015; Thomas et al., 2013; Vollenweider and Kometer, 2010] for psychedelics.”
Backgrounddos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.005 · Cited by 298
Self-citationEffective connectivity changes in LSD-induced altered states of consciousness in humans
Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J., & Vollenweider, F. X. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815129116 · Cited by 292
“Discussion Psychedelics induce an altered state of consciousness that, on the one hand, mimics predominantly positive symptoms of schizophrenia, but on the other hand, may have beneficial therapeutic effects in mood and anxiety disorders (20).”
BackgroundSelf-citationScheidegger, M., Walter, M., Lehmann, M., Metzger, C., Grimm, S., Boeker, H., Boesiger, P., Henning, A., & Seifritz, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044799 · Cited by 282
“Based on the increasing evidence of glutamate-modulating agents having strong and rapid antidepressant properties [1,2], the NMDA receptor antagonist ketamine has been firmly established as a research tool for the investigation of the neurobiology of the glutamatergic system in major depressive disorder (MDD) and nove…”
BackgroundPhenomenology, Structure, and Dynamic of Psychedelic States
Preller, K. H., & Vollenweider, F. X. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_459 · Cited by 282
“These studies suggest that 5-HT2A receptor stimulation by psilocybin may exhibit antidepressive properties and may have the potential to normalize dysfunctional negative emotional biases (Vollenweider and Kometer 2010).”
BackgroundSelf-citationClassic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates
Barrett, F. S., & Griffiths, R. R. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_474 · Cited by 273
“While double-blind studies have not rigorously compared the psychoactive effects of these and other classic hallucinogens (including synthetic hallucinogens such as LSD), the alterations in consciousness produced by these compounds are generally considered to be quite similar, putatively because they share a common me…”
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
Psilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276
“Further on, a potential future use of psilocybin in the treatment of anxiety depressive disorder is also emerging (CarhartHarris et al., 2012b; Vollenweider and Kometer, 2010).”
BackgroundInfluentialde Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
“It has been suggested that the persisting therapeutic effects of psychedelics are attributable to a similar biological mechanism (39, 40).”
BackgroundReviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
“Psychedelic drugs (sometimes referred to as hallucinogens or entactogens) refer to a category of compounds that can induce a wide range of psychological, cognitive, emotional, and physical effects (Nichols, 2004; Vollenweider and Kometer, 2010).”
BackgroundMason, N. L., Kuypers, K. P. C., Müller, F., Reckweg, J., Tse, D. H. Y., Toennes, S. W., Hutten, N. R. P. W., Jansen, J. F. A., Stiers, P., Feilding, A., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0718-8 · Cited by 258
“Furthermore, the increase in extracellular glutamate has been suggested to activate AMPA receptors located on the same neurons, increasing expression of brain-derived neurotrophic factor (BDNF) [16, 27, 28], a protein implicated in neuronal survival and growth, and decreased in pathological populations [29].”
BackgroundInfluentialMajić, T., Schmidt, T. T., & Gallinat, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568040 · Cited by 261
“With the rise of modern neuroimaging methods, new hypotheses regarding the mechanism of action of these substances in the central nervous system have been suggested (Carhart-Harris et al., 2012; Nichols and Chemel, 2006; Vollenweider and Kometer, 2010).”
BackgroundDe Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 259
“Classic hallucinogens exert their pharmacological effects primarily through the 5-HT system, acting as agonists of the 5-HT2A receptor (Vollenweider et al., 2007; Passie et al., 2008; Vollenweider and Kometer, 2010).”
Classical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256
Smigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.04.009 · Cited by 248
Self-citationMolecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 240
“Thus, confidence in translating results from acute psychedelic neuroimaging (Vollenweider and Kometer, 2010; Muthukumaraswamy et al., 2013; Carhart-Harris et al., 2014a,b, 2017b; Tagliazucchi et al., 2014; Kraehenmann et al., 2015; Scheidegger et al., 2016; Lewis et al., 2017; Schartner et al., 2017) to clinical appli…”
BackgroundKetamine for Treatment-Resistant Unipolar Depression: Current Evidence
Mathew, S. J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., & Murrough, J. W. (2012) · CNS Drugs · doi:10.2165/11599770-000000000-00000 · Cited by 238
“Ketamine appears to facilitate neural activation in regions of the PFC in humans as measured by positron emission tomography (PET) and [18F]fluorodeoxyglucose,([116,117]) consistent with the observation that ketamine results in a net increase in excitatory glutamatergic transmission in cortical regions in animals (see…”
BackgroundA systematic study of microdosing psychedelics
Polito, V., & Stevenson, R. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211023 · Cited by 235
Central 5-HT receptors and their function; present and future
Sharp, T., & Barnes, N. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108155 · Cited by 231
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Classic hallucinogens in the treatment of addictions
Bogenschutz, M. P., & Johnson, M. W. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.002 · Cited by 226
“However, the effects of all classic hallucinogens appear to depend primarily on their actions at 5HT2A receptors (Glennon et al., 1984; Halberstadt, 2015; Nichols, 2004; Vollenweider and Kometer, 2010).”
George, J. R., Michaels, T. I., Sevelius, J., & Williams, M. T. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.015 · Cited by 230
“…therapy studies were conducted that examined the effects of mescaline, LSD, psilocybin, MDMA, and other substances in the treatment of depression, anxiety, personality disorders, obsessive – compulsive disorder, addic-tions, and even sexual dysfunction (Vollenweider & Kometer, 2010).”
BackgroundPsychedelics, personality and political perspectives.
Nour, M. M., Evans, L., & Carhart-Harris, R. L. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1312643 · Cited by 226
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
“…neuroplasticity can be found in the post-synaptic effects of classic psychedelics in layer 5 of the medial prefrontal cortex, where they induce a burst of glutamate release (Vollenweider & Kometer, 2010) and sustained α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation.”
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Canal, C. E., & Morgan, D. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1333 · Cited by 221
“result of emergent outputs from communication between several neural systems,([167,168]) several studies employing pharmacological,”
The role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault-Phillips, S., Nijdam, M. J., McFarlane, A., & Vermetten, E. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 208
Kuypers, K. P., Ng, L., Erritzoe, D., Knudsen, G. M., Nichols, C. D., Nichols, D. E., Pani, L., Soula, A., & Nutt, D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119857204 · Cited by 215
“No change was observed in dendritic spine density in the layer V pyramidal neurons, and no changes were observed in gene expression (EGR1, EGR2, ARC, FOS, BDNF and 5HT2A).”
BackgroundInfluentialSoler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual, J. C., & Riba, J. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4162-0 · Cited by 209
“From a mechanistic perspective, these drugs show modulatory activity on the amygdala and the anterior cingulate cortex following acute administration (Vollenweider and Kometer 2010; Kraehenmann et al. 2014).”
BackgroundMillière, R. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00245 · Cited by 206
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“However, differential actions at other serotonergic, dopaminergic, and downstream glutamatergic targets are known to modulate the effects of distinct psychedelics (Moreno et al., 2011; Nichols, 2016; Pieri et al., 1974; Ray, 2010; Vollenweider et al., 1999; Vollenweider & Kometer, 2010).”
BackgroundRaval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020835 · Cited by 200
Sampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., Luna, L. E., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx036 · Cited by 200
“Psychedelics are the object of renewed interest as potential therapeutic tools in psychiatry (Sessa, 2005; Vollenweider and Kometer, 2010; Grob et al., 2011).”
BackgroundRaval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M. (2020) · doi:10.20944/preprints202011.0742.v1 · Cited by 200
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4453-0 · Cited by 198
“The 200 μg dose of LSD also produced greater ASC scores than high doses of the serotonergic hallucinogens DMTand psilocybin (Gouzoulis-Mayfrank et al. 2005; Hasler et al. 2004; Vollenweider and Kometer 2010), ketamine (Gouzoulis-Mayfrank et al.”
BackgroundAbnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis
Probasco, J. C., Solnes, L., Nalluri, A., Cohen, J., Jones, K. M., Zan, E., Javadi, M. S., & Venkatesan, A. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000352 · Cited by 192
Psychedelics in the treatment of unipolar mood disorders: a systematic review
Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D., & Young, A. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116679368 · Cited by 185
“…pharmacology (Passie et al., 2002; 2008), molecular neurobiology(Aghajanian and Marek, 1999; Halberstadt and Geyer, 2011; JL Moreno et al., 2011; Vollenweider and Kometer, 2010), neuroimaging correlates (Carhart-Harris et al., 2012; Carhart-Harris, Muthukumaraswamy, et al., 2016) and…”
BackgroundPsilocybin Induces Time-Dependent Changes in Global Functional Connectivity
Preller, K. H., Duerler, P., Burt, J. B., Ji, J. L., Adkinson, B., Stämpfli, P., Seifritz, E., Repovš, G., Krystal, J. H., Murray, J. D., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.12.027 · Cited by 183
Self-citationPharmacological treatment of anxiety disorders: Current treatments and future directions
Farach, F. J., Pruitt, L. D., Jun, J. J., Jerud, A. B., Zoellner, L. A., & Roy-Byrne, P. P. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2012.07.009 · Cited by 183
Smigielski, L., Kometer, M., Scheidegger, M., Krähenmann, R., Huber, T., & Vollenweider, F. X. (2019) · Scientific Reports · doi:10.1038/s41598-019-50612-3 · Cited by 176
Self-citationAlmeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177
Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting
Prochazkova, L., Lippelt, D. P., Colzato, L. S., Kuchar, M., Sjoerds, Z., & Hommel, B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5049-7 · Cited by 177
“Nonetheless, existing research with moderate doses of psilocybin shows that psilocybin is a potent neuro-pharmacological agent with a strong modulatory effect on brain processes (Vollenweider and Kometer 2010).”
BackgroundEffects of serotonin 2A/1A receptor stimulation on social exclusion processing
Preller, K. H., Pokorny, T., Hock, A., Kraehenmann, R., Stämpfli, P., Seifritz, E., Scheidegger, M., & Vollenweider, F. X. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524187113 · Cited by 169
“In the present study, the Psi-induced alterations on the 5DASC and increased scores for basic positive mood were generally similar to those observed in previous studies using comparable drug doses (10, 22).”
ResultSelf-citationFormal thought disorders: from phenomenology to neurobiology
Kircher, T., Bröhl, H., Meier, F., & Engelen, J. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30059-2 · Cited by 172
Bershad, A. K., Schepers, S. T., Bremmer, M. P., Lee, R., & de Wit, H. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.019 · Cited by 175
Morales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S., Rodríguez-Franco, M. I., Feilding, A., Perez-Castillo, A., & Riba, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-05407-9 · Cited by 175
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
dos Santos, R. G., Bouso, J. C., & Hallak, J. E. C. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316689030 · Cited by 168
“2008; Vollenweider and Kometer, 2010; Studerus et al.”
BackgroundResultInfluentialGlutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
“The notion that these networks are involved in the action of ketamine and other NMDAR antagonists is supported by human (Vollenweider and Kometer, 2010), primate (Lv et al.”
BackgroundKetamine for the treatment of addiction: evidence and potential mechanisms
Ivan Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.017 · Cited by 163
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2015-1701 · Cited by 160
Steiner, J., Bogerts, B., Sarnyai, Z., Walter, M., Gos, T., Bernstein, H.-G., & Myint, A.-M. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.583941 · Cited by 160
“In contrast, a depression-related activation of the synthesis of the NMDA receptor agonist, quinolinic acid, in microglial cells has been hypothesised, which is in line with the observed therapeutic effects of ketamine in major depression (Vollenweider and Kometer 2010).”
ResultKometer, M., Pokorny, T., Seifritz, E., & Volleinweider, F. X. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4026-7 · Cited by 176
“2003; Southwick and Charney 2012) and that psilocybin had therapeutic effects in treating mood disorders (Vollenweider and Kometer 2010) and in reducing anxiety in terminal cancer patients (Grob et al.”
BackgroundSelf-citationForstmann, M., & Sagioglou, C. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117714049 · Cited by 196
“substances are usually characterized by their action as 5-HT2A receptor agonists (Nichols, 2004; Vollenweider and Kometer, 2010).”
BackgroundInfluentialAnimal Models of Serotonergic Psychedelics
Hanks, J. B., & González-Maeso, J. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn300138m · Cited by 156
Modulations of the experience of self and time
Wittmann, M. (2015) · Consciousness and Cognition · doi:10.1016/j.concog.2015.06.008 · Cited by 180
Sarris, J. J., McIntyre, E., & Camfield, D. (2013) · CNS Drugs · doi:10.1007/s40263-013-0059-9 · Cited by 172
“Due to the fact that fronto-limbic 5-HT2A receptor density has been found to be elevated in individuals with anxiety and difficulty coping with stress [160], a possible mechanism by which psilocybin may exert therapeutic effects is through down-regulation of prefrontal 5-HT2A receptors [161].”
BackgroundTo use or not to use: an update on licit and illicit ketamine use
Li, J., Kasinather, V. B., Cheung, Zhou, Nurhidayat, Jarlais, D., & Schottenfeld, R. S. (2011) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s15458 · Cited by 163
“Besides ketamine, some psychedelic drugs, such as lysergic acid diethylamide (LSD) and psilocybin, have shown efficacy in treating obsessive-compulsive disorders and addiction as well as depression and anxiety.(46) Although ketamine-induced antidepressant effect was rapid, its adverse events including dissociation and…”
Psychedelic harm reduction and integration: A transtheoretical model for clinical practice
Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.645246 · Cited by 147
“Transference and countertransference may be particularly intensified in PHRI and psychedelic-assisted psychotherapies (Vollenweider and Kometer, 2010; Taylor, 2014; Phelps, 2017).”
BackgroundPositive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., & Carhart-Harris, R. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-81446-7 · Cited by 145
“The planned contrast analysis (simple) showed significant differences between well-being scores at baseline and all successive timepoints: week 1 [F(1, 67) = 14.”
BackgroundResultInfluentialAyahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers
Murphy-Beiner, A., & Soar, K. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05445-3 · Cited by 135
“Given the high failure rates in current treatments, the search for alternative treatment strategies is crucial (Vollenweider and Kometer 2010).”
BackgroundDakwar, E., Levin, F., Foltin, R. W., Nunes, E. V., & Hart, C. L. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.009 · Cited by 143
“In either case, the clinical framework by which the therapeutic potential of ketamine can be best harnessed and sustained is important to investigate,(36,39) as with early studies assessing Ketamine Psychedelic Therapy (KPT) for alcohol and opioid dependence.”
Taves, A. (2020) · Perspectives on Psychological Science · doi:10.1177/1745691619895047 · Cited by 140
“Although both psilocybin and ketamine often lead to experiences of unity, especially at higher doses, the most prominent effects associated with psilocybin are visual and the most prominent effect associated with ketamine is disembodiment (Vollenweider & Kometer, 2010, p. 644).”
BackgroundDe Gregorio, D., Popic, J., Enns, J. P., Inserra, A., Skalecka, A., Markopoulos, A., Posa, L., Lopez-Canul, M., He, Q., Lafferty, C. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020705118 · Cited by 139
Ross, S., Agin-Liebes, G., Lo, S., Zeifman, R. J., Ghazal, L., Benville, J., Franco Corso, S., Bjerre Real, C., Guss, J., Bossis, A., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00020 · Cited by 139
Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
Dakic, V., Minardi Nascimento, J., Costa Sartore, R., Maciel, R. D. M., de Araujo, D. B., Ribeiro, S., Martins-de-Souza, D., & Rehen, S. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12779-5 · Cited by 134
Pokorny, T., Preller, K. H., Krähenmann, R., & Vollenweider, F. X. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.01.005 · Cited by 154
“…interaction (Preller et al., 2015), while some studies have begun to reevaluate the clinical potential of psilocybin for example in the treatment of anxiety and depression in terminally ill cancer patients (Gasser et al., 2015; Grob et al., 2011; Majić et al., 2015; Vollenweider and Kometer, 2010).”
BackgroundSelf-citationSerotonin toxicity of serotonergic psychedelics
Malcolm, B., & Thomas, K. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05876-x · Cited by 138
“2017; Liechti 2017; 1 3 Vollenweider and Kometer 2010).”
Inflammatory signaling mechanisms in bipolar disorder
Jones, G. H., Vecera, C. M., Pinjari, O. F., & Machado‐Vieira, R. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00742-6 · Cited by 160
Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4769-4 · Cited by 133
“…of classic hallucinogens and dissociative anesthetic hallucinogens may involve underlying common mechanisms of action including interactions of serotonergic and glutamatergic neurotransmitter systems (Aghajanian and Marek 1999; Fantegrossi et al. 2008; Nichols 2016; Vollenweider and Kometer 2010).”
BackgroundSpontaneous and deliberate creative cognition during and after psilocybin exposure
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T., Müller, F., Tse, D. H. Y., Rios, B. D., Toennes, S. W., Stiers, P. L. J., Feilding, A., & Ramaekers, J. G. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01335-5 · Cited by 155
Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 162
Zebrafish neurobehavioral phenomics for aquatic neuropharmacology and toxicology research
Kalueff, A. V., Echevarria, D. J., Homechaudhuri, S., Stewart, A., Collier, A. D., Kaluyeva, A. A., Li, S., Liu, Y., Chen, P., Wang, J., et al. (2015) · Aquatic Toxicology · doi:10.1016/j.aquatox.2015.08.007 · Cited by 141
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
Johnson, M. W., Garcia‐Romeu, A., Johnson, P. S., & Griffiths, R. R. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116684335 · Cited by 140
“Such effects may be related to psychedelics’ serotonergic mechanism of action at the 5-HT2A and possibly 5-HT1A receptors (Bogenschutz and Pommy, 2012; Kraehenmann et al., 2014; Preller et al., 2016; Ross, 2012; Vollenweider and Kometer, 2010).”
Background
Metadata
- Authors
- Vollenweider, F. X., & Kometer, M.
- Affiliations
- University of Zurich (CH)
- University Hospital Zurich (CH)
- Corresponding author
- Vollenweider, Franz X.
- Venue
- Nature Reviews Neuroscience
- Published
- 2010-08-18
- Volume
- 11
- Issue
- 9
- Pages
- 642-651
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2068751924
- Semantic Scholar
- d95a57f4b1e3288f21a7dab08ebc2fd5ff10a762
- Cited by
- 723
- References
- 149
- Citations by year
- 2026: 55 · 2025: 75 · 2024: 55 · 2023: 64 · 2022: 53 · 2021: 63 · 2020: 50 · 2019: 35 · 2018: 56 · 2017: 37 · 2016: 48 · 2015: 29 · 2014: 24 · 2013: 18 · 2012: 25
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psychedelics, mood disorders, serotonergic system, glutamatergic system, dissociative anesthetics, LSD, psilocybin, ketamine, neuroplasticity, neural circuits, psychiatric treatment
- MeSH terms
- Animals, Brain, Hallucinogens, Humans, Models, Neurological, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.